REG - Goldman Sachs & Co. Willis Towers Watson - Form 38.5(b) - Willis Towers Watson plc

Willis Towers WatsonAnnouncement

09/06/2021 11:50

RNS Number : 3459B
  
Goldman Sachs & Co. LLC
  
09 June 2021
  
 

 
FORM 38.5(b)
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
 
1. KEY INFORMATION
 



Name of exempt principal trader


GOLDMAN SACHS & CO. LLC




Company dealt in


WILLIS TOWERS WATSON PLC




Class of relevant security to which the dealings being disclosed relate (Note1)


USD 0.000304635 ordinary shares




Date of dealing


08 June 2021



 
2. INTERESTS AND SHORT POSITIONS
 
(a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)
 



 


Long


Short




 


Number


(%)


Number


(%)




(1) Relevant securities 


2,208,157.542


(1.71)


2,283,965.542


(1.77)




(2) Derivatives (other than options)


642,470


(0.49)


2,626,630


(2.03)




(3) Options and agreements to purchase/sell


0


(0.00)


0


(0.00)




Total


2,850,627.542


(2.21)


4,910,595.542


(3.80)



 
(b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)
 



Class of relevant security:


Long


Short




 


Number


(%)


Number


(%)




(1) Relevant securities 


 


 


 


 




(2) Derivatives (other than options)


 


 


 


 




(3) Options and agreements to purchase/sell


 


 


 


 




Total


 


 


 


 



 
3.    DEALINGS (Note 3)
(a) Purchases and sales
 



Purchase/sale


Number of relevant securities


Price per unit  (Note 4)




Purchase


96


253.8800 USD




Purchase


85


254.5700 USD




Purchase


1,776


254.5700 USD




Purchase


1


254.5700 USD




Purchase


30


254.5700 USD




Purchase


26


254.5700 USD




Sale


14


253.6600 USD




Sale


100


253.7150 USD




Sale


93


254.5700 USD




Sale


100,000


254.5700 USD




Sale


10


254.5700 USD




Sale


151


254.5700 USD




Sale


24


254.5700 USD




Sale


1


254.5700 USD




Sale


1,748


254.5700 USD




Sale


25


254.5700 USD




Sale


228


254.5700 USD




Sale


1,442


254.5700 USD




Sale


7


254.5700 USD




Sale


5


254.5700 USD




Sale


100


256.3800 USD




Sale (Loan Adjust)


317


N/A




Sale (Loan Adjust)


326


N/A




Purchase (Loan Partial Return)


157,000


N/A



 
(b) Derivatives transactions (other than options transactions)
 



Product name, e.g. CFD


Nature of transaction  (Note 5)


Number of relevant securities  (Note 6)


Price per unit  (Note 4)




CFD


Opening a long position


14


253.6596 USD



 
(c) Options transactions in respect of existing relevant securities
 
(i) Writing, selling, purchasing or varying
 



Product name,e.g. call option


Writing, selling,  purchasing, varying etc.


Number of securities to which the option relates  (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit  (Note 4)




 


 


 


 


 


 


 



 
(ii)            Exercising 
 



Product name,e.g. call option


Number of securities


Exercise price per unit  (Note 4)




 


 


 



 
(d)            Other dealings (including transactions in respect of new securities)  (Note 3)
 



Nature of transaction  (Note 7)


Details


Price per unit (if applicable)  (Note 4)




 


 


 



 
4. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 



Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.  If none, this should be stated.  




NONE



 
Is a Supplemental Form 8 attached? (Note 9)        YES 
 



Date of disclosure


09 June 2021




Contact name


Paul Grainger and Kashif Rafiq




Telephone number


+44(20) 7552 9835 / +44(20) 7051 0547




Name of offeree/offeror with which connected


WILLIS TOWERS WATSON PLC




Nature of connection (Note 9)


Advisor to Offeree



 
SUPPLEMENTAL FORM 38.5(b)
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DETAILS OF OPEN POSITIONS
 
OPEN POSITIONS (Note 1)
 



Product name,e.g. call option


Written or purchased


Number of relevant securities to which the option or derivative relates


Exercise price (Note 2)


Type, e.g. American, European etc. 


Expiry date




Swap


Sold


185


0.0000 


N/A


23/09/2021




Swap


Sold


562


0.0000 


N/A


29/06/2021




Swap


Sold


36,084


0.0000 


N/A


16/05/2022




Swap


Sold


84,311


0.0000 


N/A


16/05/2022




Swap


Sold


140,000


0.0000 


N/A


24/03/2022




Swap


Sold


140,000


0.0000 


N/A


25/03/2022




Swap


Purchased


597,000


0.0000 


N/A


04/01/2023




Swap


Sold


597,000


0.0000 


N/A


04/01/2023



 
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ISEUPUACQUPGGUB